Search Results
664 results
Your search is now limited to «Leukemia» expert search.
Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense.
More from International Journal of COPD:
Medical Research News 01/21/2019 17:31
MedicalResearch.com. MedicalResearch.com Interview with: Dr. Marie Joelle Jabagi, PharmD, MPH University of Paris Sud, Paris-Saclay University, Paris Health Product Epidemiology Department French National Agency for Medicines and Health Products Safety Saint-Denis, France MedicalResearch.com: What is the background for this study?
More from Medical Research News:
FierceMedicalDevices 01/21/2019 17:03
... with Be The Match Biotherapies, a service-focused subsidiary of the National Marrow Donor Program, to help support the late-phase development of its cell therapy that aims to offer an alternative source of universal bone marrow transplant material for patients with blood cancers.
More from FierceMedicalDevices:
Treatments include blood transfusions, bone marrow transplants and medication to help the body make more red blood cells.
More from Mail on Sunday (United Kingdom):
BioNewsFeeds 01/21/2019 13:49
A Phase 1/2 trial is evaluating Loxo Oncology‘s BTK inhibitor LOXO-305 in leukemia and lymphoma patients who failed, or were intolerant to, approved BTK inhibitors.
More from BioNewsFeeds:
WN.com 01/21/2019 11:24
Tiny scratch on baby boy’s eye turns out to be sign of rare form of leukaemia.
More from WN.com:
NaturalNews.com 01/21/2019 01:02
Natural News) Patients with chronic myeloid leukemia, who often suffer from anxiety, may find relief in bitter orange (Citrus aurantium L.) essential oil.
More from NaturalNews.com:
PubMed News (NIH) 01/18/2019 23:00
Contributor : Amitava Sengupta Series Type : Genome binding/occupancy profiling by high throughput sequencing Organism : Homo sapiens. We have used chromatin immunoprecipitation followed by high throughput sequencing to map regions of chromatin remodeler binding in Control and KDM6A knock down AML cells.
More from PubMed News (NIH):
Healio News 01/18/2019 20:00
Trials explore optimal treatments, resistance in chronic lymphocytic leukemia.
More from Healio News:
ecancer news 01/18/2019 17:00
The historically poor prognosis has prompted many leukaemia specialists to advocate for treating these patients with intensive chemotherapy followed by allogeneic bone marrow transplantation.
More from ecancer news:
BIOENGINEER.ORG 01/18/2019 16:13
Study led by St. Jude Children’s Research Hospital found treatment guided by measuring minimal residual disease was associated with better outcomes for hypodiploid acute lymphoblastic leukemia patients Credit: St. Jude Children’s Research Hospital Checking for minimal residual disease early in treatment can help some young high-risk leukemia patients avoid bone marrow transplantation without compromising their [...]
More from BIOENGINEER.ORG:
Pharmafile 01/18/2019 04:58
... means that thousands of patients in England and Wales will be able to receive Abbvie’s Venclyxto (venetoclax) in combination with Genentech’s Rituxan (rituximab) on the NHS as a treatment for relapsed or refractory chronic lymphocytic leukaemia (CLL) following one prior therapy.
More from Pharmafile:
Journal of Clinical Oncology, Ahead of Print.
More from American Society of Clinical Oncolgy (ASCO):
Business Wire 01/17/2019 18:30
... Assay has been granted De Novo designation by the FDA as an in vitro diagnostic (IVD) to detect and monitor minimal residual disease (MRD) in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) using DNA from bone marrow samples.
More from Business Wire:
ClinicalTrials.gov 01/17/2019 08:51
Condition : Leukemia, Myeloid, Chronic-Phase Intervention : Drug: Ponatinib Sponsors : GWT-TUD GmbH; Incyte Biosciences International Sàrl Recruiting.
More from ClinicalTrials.gov:
News-Medical.net 01/17/2019 02:26
But researchers from the University of Sussex, Bristol and Cardiff using funding from the Kay Kendall Leukaemia Fund (KKLF) and Bloodwise have now discovered a protein partner that promotes this process and therefore helps leukemia cells to grow.
More from News-Medical.net:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications